Clinical Trial

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Name: Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression — clinical trial record (NCT06560528)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.

Trial Details

NCT Number	NCT06560528
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment	40 participants
Start Date	2024-09-01
Primary Completion	2027-09-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-19